Overview

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i Obinutuzumab

Status:
NOT_YET_RECRUITING

Trial end date:
2032-11-30

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi + BCL2i therapy ( obinutuzumab) and maintained a response for at least two years post-treatment.

Phase:

PHASE2

Details

Lead Sponsor:

AstraZeneca

Collaborators:

AbbVie
Genentech, Inc.

Treatments:

acalabrutinib
venetoclax